Sensei Biotherapeutics Inc 2024年度报告

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).YES☒NO☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or anemerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growthcompany” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any newor revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internalcontrol over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm thatprepared or issued its audit report.☐ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in thefiling reflect the correction of an error to previously issued financial statements.☐Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).☐ As of June 28, 2024 (the last business day of the Registrant’s second fiscal quarter), the Registrant's aggregate market value of its voting common equityheld by non-affiliates was approximately $10.3million based on the closing sale price of $0.62 per share as reported on the Nasdaq Global Market on thatdate. The number of shares of Registrant’s Common Stock outstanding as of March 24, 2025 was25,208,068. DOCUMENTS INCORPORATED BY REFERENCEPortions of the Registrant’s definitive proxy statement, to be filed pursuant to Regulation 14A under the Securities Exchange Act of 1934, for its 2025 Annual Meeting of Stockholders are incorporated by reference in Part III of this Form 10-K. Table of Contents PART I Item 1.BusinessItem 1A.Risk FactorsItem 1B.Unresolved Staff CommentsItem 1C.CybersecurityItem 2.PropertiesItem 3.Legal ProceedingsItem 4.Mine Safety Disclosures PART IIItem 5.Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases ofEquity Securities74Item 6.Reserved74Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations75Item 7A.Quantitative and Qualitative Disclosures About Market Risk83Item 8.Financial Statements and Supplementary Data83Item 9.Changes in and Disagreements With Accountants on Accounting and Financial Disclosure83Item 9A.Controls and Procedures83Item 9B.Other Information84Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections84 PART III Item 10.Directors, Executive Officers and Corporate Governance85Item 11.Executive Compensation85Item 12.Security Ownership of Certain Beneficial Owners and Management and Related StockholderMatters85Item 13.Certain Relationships and Related Transactions, and Director Independence85Item 14.Principal Accounting Fees and Services85 PART IV Cautionary Notice Regarding Forward-Looking Statement All statements other than statements of historical fact included in this Annual Report on Form 10-K (“Report”),including, without limitation, statements under “Business” and “Management’s Discussion and Analysis ofFinancial Condition and Results of Operations” regarding our financial position, business strategy and the plans andobjectives of management for future operations, are forward-looking statements. When used in this Report, wordsand phrases such as “designed to,” “intended to,” “may,” “might,” “can,” “will,” “to be,” “could,” “would,”“should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,”“potential,” “likely,” “continue” and “ongoing,” or the negative of such terms or other similar expressions, as theyrelate to us or our management, identify forward-looking statements. Any statements in this Report, or incorporated herein, about our expectations, beliefs, plans, objectives, assumptionsor future events or performance are not historical facts and are forward-looking statements within the meaning ofSection 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements includestatements regarding: •the ability of our preclinical studies and clinical trials to demonstrate acceptable safety and efficacy ofour product candidates;•business disruptions affecting t